DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Clinical trials for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new DLBCL - DIFFUSE LARGE B CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Double-Punch combo trial aims to knock out tough lymphoma
Disease control Not yet recruitingThis study is testing whether combining two powerful treatments—CAR-T cell therapy and a drug called glofitamab—is safe and effective for people with high-risk, relapsed, or hard-to-treat large B-cell lymphoma. It will enroll about 24 participants at a single hospital in China. T…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New trial pits two drug combos against Tough-to-Treat lymphoma return
Disease control Not yet recruitingThis study aims to find out which of two different chemotherapy combinations works better for people whose diffuse large B-cell lymphoma has come back more than a year after initial treatment. About 70 participants will be randomly assigned to receive one of the two drug regimens…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: NA • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New hope for lymphoma patients: testing a Chemotherapy-Free treatment
Disease control Not yet recruitingThis study aims to test whether a combination of three targeted drugs (glofitamab, polatuzumab vedotin, and zuberitamab) can effectively treat newly diagnosed diffuse large B-cell lymphoma without using traditional chemotherapy. It will enroll 40 adults who have not yet received …
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Li Zhiming • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Scientists track patients for 15 years after revolutionary cancer cell therapy
Disease control Not yet recruitingThis study aims to monitor the long-term safety and persistence of a CAR-T cell therapy called GF-CART01 for up to 15 years. It will follow 18 patients who previously received this treatment for aggressive B-cell lymphomas that have returned or not responded to other therapies. T…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Sponsor: GenomeFrontier Therapeutics TW Co., Ltd. • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New hope for Tough-to-Treat lymphoma patients in Real-World setting
Disease control Not yet recruitingThis study will observe how well the drug glofitamab works for patients with aggressive lymphoma that didn't respond to initial treatment or returned quickly. Doctors will follow about 20 patients receiving this treatment as part of their regular care to see how they respond and …
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC